Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
July 17, 2025 6:59 AM EDTEliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price
PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis® (apixaban) via our Alliances patient resource... More
